Oral squamous cell carcinoma is the most common malignancy of the oral cavity, and treatment approaches are inadequate. Luteolin, a natural flavonoid compound, has been shown to have anti-tumorigenic properties on various types of tumors. Therefore, we hypothesized that luteolin has anti-tumorigenic properties for oral squamous cell carcinoma, and may provide effective chemotherapy. Results revealed that luteolin reduced the viability of SCC-4 cells and induced apoptosis by decreasing the expression of cyclin-dependent kinase (CDKs), cyclins, and phosphor- retinoblastoma (p-Rb) anti-apoptotic protein, but increased the expression of pro-apoptotic proteins and activated caspase 9 and 3, with a concomitant increase in the levels of cleaved poly-ADP-ribose polymerase (PARP). Combination treatment of luteolin with paclitaxel enhanced the cytotoxic effect of paclitaxel in SCC-4 cells, and continuous administration of luteolin suppressed the growth of xenograft tumors in nude mice. These results suggest that luteolin could be an effective chemotherapeutic agent for the treatment of oral squamous cell carcinoma.
Get full access to this article
View all access options for this article.
References
1.
Block G, Patterson B, Subar A -1992-. Fruit, vegetables, and cancer prevention: a review of the epidemiological evidence. Nutr Cancer18:1–29.
2.
Browning AM, Walle UK, Walle T -2005-. Flavonoid glycosides inhibit oral cancer cell proliferation—role of cellular uptake and hydrolysis to the aglycones. J Pharm Pharmacol57:1037–1041.
3.
Chen PN, Hsieh YS, Chiang CL, Chiou HL, Yang SF, Chu SC -2006-. Silibinin inhibits invasion of oral cancer cells by suppressing the MAPK pathway. J Dent Res85:220–225.
4.
Dermitzaki E, Tsatsanis C, Gravanis A, Margioris AN -2002-. Corticotropin-releasing hormone induces Fas ligand production and apoptosis in PC12 cells via activation of p38 mitogen-activated protein kinase. J Biol Chem277:12280–12287.
5.
Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. -2003-. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med349: 2091–2098.
6.
Fotsis T, Pepper MS, Aktas E, Breit S, Rasku S, Adlercreutz H, et al. -1997-. Flavonoids, dietary-derived inhibitors of cell proliferation and in vitro angiogenesis. Cancer Res57: 2916–2921.
7.
Grañna X, Reddy EP -1995-. Cell cycle control in mammalian cells: role of cyclins, cyclindependent kinases -CDKs-, growth suppressor genes and cyclin-dependent kinase inhibitors -CKIs-. Oncogene11:211–219.
8.
Harnly JM, Doherty RF, Beecher GR, Holden JM, Haytowitz DB, Bhagwat S, et al. -2006-. Flavonoid content of U.S. fruits, vegetables, and nuts. J Agric Food Chem54:9966–9977.
9.
Havsteen B -1983-. Flavonoids, a class of natural products of high pharmacological potency. Biochem Pharmacol32:1141–1148.
10.
Herrmann K -1976-. Flavonols and flavonones in food plants. J Food Technol11:433–448.
11.
Hertog MGL, Hollman PCH, Katan MB, Kromhout D -1993-. Intake of potentially anticarcinogenic flavonoids and their determinants in adults in Netherlands. Nutr Cancer20:21–29.
12.
Hsiao YC, Kuo WH, Chen PN, Chang HR, Lin TH, Yang WE, et al. -2007-. Flavanone and 2′-OH flavanone inhibit metastasis of lung cancer cells via down-regulation of proteinases activities and MAPK pathway. Chem Biol Interact167:193–206.
13.
Hsieh YS, Chu SC, Yang SF, Chen PN, Liu YC, Lu KH -2007-. Silibinin suppresses human osteosarcoma MG-63 cell invasion by inhibiting the ERK-dependent c-Jun/AP-1 induction of MMP-2. Carcinogenesis28:977–987.
14.
Hsu S, Singh B, Schuster G -2004-. Induction of apoptosis in oral cancer cells: agents and mechanisms for potential therapy and prevention. Oral Oncol40:461–473.
15.
Huang YT, Hwang JJ, Lee PP, Ke FC, Huang JH, Huang CJ, et al. -1999-. Effects of luteolin and quercetin, inhibitors of tyrosine kinase, on cell growth and metastasis-associated properties in A431 cells overexpressing epidermal growth factor receptor. Br J Pharmacol128:999–1010.
16.
Jordan RC, Daley T -1997-. Oral squamous cell carcinoma: new insights. J Can Dent Assoc63:517–518, 521–525.
17.
Levi F, Pasche C, La Vecchia C, Lucchini F, Franceschi S, Monnier P -1998-. Food groupsand risk of oral and pharyngeal cancer. Int J Cancer77:705–709.
18.
Miller AB, Hoogstraten B, Staquet M, Winkler A -1981-. Reporting results of cancer treatment. Cancer47:207–214.
19.
Pettit GR, Hoard MS, Doubek DL, Schmidt JM, Pettit RK, Tackett LP, et al. -1996-. Actinoplastic agents 338. The cancer cell growth inhibitory constituents of Terminalia arjuna -Combretaceae-. J Ethnopharmacol53:57–63
20.
Post JF, Varma RS -1992-. Growth inhibitory effects of bioflavonoids and related compounds on human leukemic CEM-C1 and CEM-C7 cells. Cancer Lett67:207–213.
21.
Psyrri A, Kwong M, DiStasio S, Lekakis L, Kassar M, Sasaki C, et al. -2004-. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up. J Clin Oncol22:3061–3069.
22.
Sakagami H, Oi T, Satoh K -1999-. Prevention of oral diseases by polyphenols. In Vivo13:155–172.
23.
Shen SC, Ko CH, Tseng SW, Tsai SH, Chen YC -2004-. Structurally related antitumor effects of flavanones in vitro and in vivo: involvement of caspase 3 activation, p21 gene expression, and reactive oxygen species production. Toxicol Appl Pharmacol197:84–95.
24.
Shi RX, Ong CN, Shen HM. -2005-. Protein kinase C inhibition and x-linked inhibitor ofapoptosis protein degradation contribute to the sensitization effect of luteolin on tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in cancer cells. Cancer Res65:7815–7823.
25.
Shimoi K, Masuda S, Furugori M, Esaki S, Kinae N -1994-. Radioprotective effect of antioxidative flavonoids in gamma-ray irradiated mice. Carcinogenesis15:2669–2672.
26.
Sigounas G, Sallah S, Sigounas VY -2004-. Erythropoietin modulates the anticancer activity of chemotherapeutic drugs in a murine lung cancer model. Cancer Lett214:171–179.
27.
Singh RP, Dhanalakshmi S, Agarwal R -2002-. Phytochemicals as cell cycle modulators—a less toxic approach in halting human cancers. Cell Cycle1:156–161.
28.
Walle T -2004-. Absorption and metabolism of flavonoids. Free Radic Biol Med36:829–837.
29.
Walle T, Browning AM, Steed LS, Reed SG, Walle UK -2005-. Flavonoid glucosides are hydrolyzed and thus activated in the oral cavity in humans. J Nutr135:48–52.
30.
Yamamoto H, Sakakibara J, Nagatsu A, Sekiya K -1998-. Inhibitors of arachidonate lipoxygenase from defatted perilla seed. J Agric Food Chem46:862–865.
31.
Yasukawa K, Takido M, Takeuchi M, Nakagawa S -1989-. Effect of chemical constituents from plants on 12-O-tetradecanoylphorbol-13-acetate-induced inflammation in mice. Chem Pharm Bull37:1071–1073.
32.
Zi X, Simoneau AR -2005-. Flavokawain A, a novel chalcone from kava extract, induces apoptosis in bladder cancer cells by involvement of Bax protein-dependent and mitochondria-dependent apoptotic pathway and suppresses tumor growth in mice. Cancer Res65:3479–3486.
